Literature DB >> 20425260

Proteomic and metabolomic profiles in atherothrombotic vascular disease.

Roxana Martinez-Pinna1, Coral Barbas, Luis Miguel Blanco-Colio, Jose Tunon, Priscila Ramos-Mozo, Juan Antonio Lopez, Olivier Meilhac, Jean-Baptiste Michel, Jesus Egido, José Luis Martin-Ventura.   

Abstract

Atherothrombosis remains a major cause of morbidity and mortality in the western world. The underlying processes associated with clinical expression of atherothrombosis include oxidative stress and proteolysis in relation to neovascularisation and intraplaque hemorrhages, leading to immuno-inflammatory response, cell death, and extracellular matrix breakdown. The complex biological multifactorial nature of atherothrombosis requires the development of novel technologies that allow the analysis of cellular and molecular processes responsible for the transition to disease phenotypes and the discovery of new diagnostic and prognostic biomarkers. In the present article, we have reviewed recent advances in the application of proteomic and metabolomic techniques to the study of atherothrombosis. We have focused on recent studies analyzing cells involved in hemo-thrombus formation (platelets, red blood cells, and polymorphonuclear cells), as well as tissues, tissue-conditioned media, and plasma of atherothrombotic patients. In the future, the application of these high-throughput technologies, along with imaging techniques, in systems biology approaches will help to individualize medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425260     DOI: 10.1007/s11883-010-0102-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  46 in total

1.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics.

Authors:  Joanne T Brindle; Henrik Antti; Elaine Holmes; George Tranter; Jeremy K Nicholson; Hugh W L Bethell; Sarah Clarke; Peter M Schofield; Elaine McKilligin; David E Mosedale; David J Grainger
Journal:  Nat Med       Date:  2002-11-25       Impact factor: 53.440

Review 2.  The human red blood cell proteome and interactome.

Authors:  Steven R Goodman; Anastasia Kurdia; Larry Ammann; David Kakhniashvili; Ovidiu Daescu
Journal:  Exp Biol Med (Maywood)       Date:  2007-12

3.  The intraluminal thrombus as a source of proteolytic activity.

Authors:  Jesper Swedenborg; Per Eriksson
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

4.  C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function.

Authors:  Fleur Bossi; Lucia Rizzi; Roberta Bulla; Alessandra Debeus; Claudio Tripodo; Paola Picotti; Elena Betto; Paolo Macor; Carlo Pucillo; Reinhard Würzner; Francesco Tedesco
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  Subproteome analysis of the neutrophil cytoskeleton.

Authors:  Ping Xu; Mark Crawford; Michael Way; Jasminka Godovac-Zimmermann; Anthony W Segal; Marko Radulovic
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

6.  Thrombus versus wall biological activities in experimental aortic aneurysms.

Authors:  Michèle Coutard; Ziad Touat; Xavier Houard; Anne Leclercq; Jean-Baptiste Michel
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

7.  Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction.

Authors:  Klaus Distelmaier; Christopher Adlbrecht; Johannes Jakowitsch; Susanne Winkler; Daniela Dunkler; Christopher Gerner; Oswald Wagner; Irene M Lang; Markus Kubicek
Journal:  Thromb Haemost       Date:  2009-09       Impact factor: 5.249

8.  Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors.

Authors:  Weihai He; Frederick J-P Miao; Daniel C-H Lin; Ralf T Schwandner; Zhulun Wang; Jinhai Gao; Jin-Long Chen; Hui Tian; Lei Ling
Journal:  Nature       Date:  2004-05-13       Impact factor: 49.962

9.  Organellar proteomics of human platelet dense granules reveals that 14-3-3zeta is a granule protein related to atherosclerosis.

Authors:  Laura Hernandez-Ruiz; Federico Valverde; Maria D Jimenez-Nuñez; Esther Ocaña; Ana Sáez-Benito; Javier Rodríguez-Martorell; Juan-Carlos Bohórquez; Aurelio Serrano; Felix A Ruiz
Journal:  J Proteome Res       Date:  2007-10-06       Impact factor: 4.466

10.  Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.

Authors:  Iris Baumgartner; Alan T Hirsch; Maria Teresa B Abola; Patrice P Cacoub; Don Poldermans; Philippe Gabriel Steg; Mark A Creager; Deepak L Bhatt
Journal:  J Vasc Surg       Date:  2008-07-17       Impact factor: 4.268

View more
  5 in total

Review 1.  New technologies personalize diagnostics and therapeutics.

Authors:  Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

2.  Dietary oil modifies the plasma proteome during aging in the rat.

Authors:  Mónica Santos-González; José López-Miranda; Francisco Pérez-Jiménez; Plácido Navas; José M Villalba
Journal:  Age (Dordr)       Date:  2011-04-07

Review 3.  Omics-based approaches to understand mechanosensitive endothelial biology and atherosclerosis.

Authors:  Rachel D Simmons; Sandeep Kumar; Salim Raid Thabet; Sanjoli Sur; Hanjoong Jo
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-06-24

4.  Metabolomic analyses for atherosclerosis, diabetes, and obesity.

Authors:  Fuyong Du; Anthony Virtue; Hong Wang; Xiao-Feng Yang
Journal:  Biomark Res       Date:  2013-04-01

Review 5.  The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective.

Authors:  Naomi J Rankin; David Preiss; Paul Welsh; Karl E V Burgess; Scott M Nelson; Debbie A Lawlor; Naveed Sattar
Journal:  Atherosclerosis       Date:  2014-09-30       Impact factor: 5.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.